ASCO 2025 at a glance
Prepare for ASCO 2025 with LucidQuest’s concise preview, highlighting must-see sessions and key trends in oncology, from breakthrough cancer treatments to cutting-edge uses of AI in clinical practice.
📅 Build your schedule around the topics that interest you. 📥 Download the ASCO 2025_Preview_by_LucidQuest
Dive deeper
Key Topics From ASCO 2025 Scientific Presentations
Lung Cancer
-
Benmelstobart + chemo → anlotinib tops tislelizumab.
-
HLX07 + serplulimab active in EGFR-high sqNSCLC.
-
Bispecifics & vaccines move to pivotal trials. 🫁🚀
GI / GU
-
Allo-316 CAR-T hits ccRCC.
-
Epigenetic priming boosts PSMA-RLT.
-
#AI steers #NMIBC management. 🍎🎯
Pediatric Oncology
-
Naxitamab + HITS/ICE lifts r/r neuroblastoma responses.
-
Luveltamab ADC moves in #AML.
-
ctDNA WGS personalizes sarcoma tracking. 🩺
Head & Neck
-
Brentuximab + pembrolizumab in mHNSCC.
-
Chemo-IO shrinkage enables function-saving surgery.
-
Nimotuzumab + RT lowers tox in NPC. 🗣️
Breast Cancer
-
Olaparib/carboplatin ups pCR in BRCA1/2 eTNBC.
-
CE/BZA cuts ER+ DCIS proliferation.
-
APBI halves high-grade toxicity vs WBI. 🎗️
Endocrine Resistance
-
Elacestrant mixes safely.
-
RLY-2608 hits PIK3CA.
-
Inavolisib + palbociclib + fulvestrant extends OS. 💊🔄
HER2+
-
Zongertinib & BAT8010 show ORR to 58%.
-
BCI testing alters extended ET in 41% of cases.
-
⁶⁸Ga-FAPI PET guides brain-mets care. 🧩🎯
TNBC
-
Camrelizumab combos post ORR 71%.
-
SHR-A1811 + adebrelib 6-mo PFS 86%.
-
CXCL9/10 signal pembrolizumab benefit. 🥊💥
Prostate
-
SBRT + ADT gives PSA < 0.1 in 80%.
-
LuPSMA + ipilimumab/nivolumab lifts PFS but with ↑ tox.
-
Pasritamig bispecific posts PSA50 42%. 🔬🛡️
Biomarkers
-
PD-L1 IC-high/TPS-low NSCLC gains from nivolumab + ipilimumab.
-
ctDNA MRD flags high-risk peri-NSCLC.
-
Neutrophils predict mesothelioma ICI response. 🏷️🧪
Artificial Intelligence and Machine Learning at ASCO 2025
Evidence AI
-
ASCOmind reviews myeloma abstracts in <5 min, streamlining updates. ⚡️📚
LLM Tools
-
Llama 3.1 tags AEs at 98% sensitivity; Synapsis screens trials 170× faster. 🤖📝
Predictive EHR
-
XGBoost + LLM notes cut 30-day admits by 22%, saving beds. 🏥💡
Smart Imaging
-
DL MRI grades ICANS; ultrasound pCR prediction hits 94% sensitivity. 🖥️🔍
Digital Pathology
-
AI HER2 score beats pathology; local fine-tuned DL boosts ER call AUROC 0.85. 🔬📈
Radiomics
-
3-D model predicts PD-L1 (F1 76%); spatial AI biomarker tops PD-L1 alone. 📊🎯
CAR-T Risk
-
XGBoost links malnutrition to 3× mortality in CAR-T cohorts. 🍽️⚠️
Serum AI
-
Random forest detects RCC via serum (AUC 0.76); CSF gene set predicts CNS mets (AUC 0.886). 🩸🔎
Drug Discovery
-
AI docking finds USP21 inhibitors for NSCLC immune evasion. 💻🧪
📅 Build your schedule around the topics that interest you.
📥 Download the ASCO 2025_Preview_by_LucidQuest
Contact us for end-to-end conference coverage.